Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 249Rectal Neoplasms 154Pancreatic Neoplasms 125Stomach Neoplasms 105Colonic Neoplasms 104Esophageal Neoplasms 90Neoplasm Metastasis 69Breast Neoplasms 61Squamous Cell Carcinoma of Head and Neck 47Carcinoma, Hepatocellular 42Adenocarcinoma Of Esophagus 41Head and Neck Neoplasms 39Esophageal Squamous Cell Carcinoma 38Neoplasms 37Nasopharyngeal Carcinoma 30Adenocarcinoma 24Cholangiocarcinoma 20Keratosis, Actinic 17Carcinoma, Squamous Cell 16Biliary Tract Neoplasms 16Liver Neoplasms 15Gastrointestinal Neoplasms 15Anus Neoplasms 14Gallbladder Neoplasms 11Bile Duct Neoplasms 11Peritoneal Neoplasms 10Laryngeal Neoplasms 9Recurrence 8Nasopharyngeal Neoplasms 7Colorectal Cancer Metastatic 7

Interventions

Oxaliplatin 2Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Cancer × Fluorouracil × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡